Dr. Lal Pathlabs Ltd

Dr. Lal Pathlabs Board Meeting Date

Dr. Lal PathLabs' Board will meet on July 24, 2026. The meeting agenda includes approving quarterly results and considering an interim dividend.

Dr. Lal Pathlabs Other Announcement

Dr. Lal PathLabs has sent letters to shareholders without registered emails. The communication provides a web-link to access the Annual Report for FY 2025-26.

Dr. Lal Pathlabs Annual Report

Dr. Lal PathLabs reported FY2025-26 revenue of ₹2,762.9 Crore and PAT of ₹509.8 Crore. The annual report highlights 312 labs, 3.22 MW solar capacity and CSR spend of ₹102.2 Crore.

Value

₹2,763 Cr

Dr. Lal Pathlabs Business Update

Dr. Lal PathLabs submitted its Business Responsibility & Sustainability Report for FY 2025‑26 to the NSE. The filing details its ESG initiatives and employee statistics.

Dr. Lal Pathlabs Annual General Meeting

Dr. Lal PathLabs Ltd has issued a notice for its 32nd Annual General Meeting on 25 July 2026. Shareholders are invited to attend via video conferencing.

Dr. Lal Pathlabs Board Meeting Date

Dr. Lal PathLabs scheduled a Board meeting on 24‑Jul‑2026 to approve its unaudited QJune‑30‑2026 results. Trading window will be closed from 1 to 26 July 2026.

Dr. Lal Pathlabs Merger & Restructuring Worth ₹49.75 Cr

Dr. Lal PathLabs incorporated a new wholly owned subsidiary in Dubai for ₹49.75 Crore. The entity will focus on international diagnostic service expansions and strategic investments.

Value

₹49.75 Cr

Dr. Lal Pathlabs Merger & Restructuring

Dr. Lal PathLabs Ltd incorporated a wholly owned subsidiary in Dubai named DR LAL PATHLABS FZCO. This subsidiary will focus on diagnostics and allied activities, including potential acquisitions and joint ventures.

Dr. Lal Pathlabs Earnings Call: Key Takeaways

Dr. Lal PathLabs reported strong Q4 FY26 results with 16.6% revenue growth. Focus remains on expansion through 1,100+ new collection centers and high-end diagnostic branding.

Dr. Lal Pathlabs Acquisition Worth ₹20 Cr

Dr. Lal Path Labs Ltd. has completed the 100% acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL) for ₹20 Crore. Following the transaction, SDCPL has become a wholly owned subsidiary of the company. This acquisition strengthens the company's diagnostic footprint.

Value

₹20.00 Cr

Dr. Lal Pathlabs Acquisition

Dr. Lal PathLabs Ltd. has successfully completed the 100% acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL) on May 01, 2026. SDCPL is now a wholly-owned subsidiary of the company, following the terms of the Share Purchase Agreement signed on April 30, 2026.

Dr. Lal Pathlabs Board Meeting Outcome

Dr. Lal PathLabs announced the re-appointment of (Hony) Brig. Dr. Arvind Lal as Executive Chairman for five years from April 2027. The board also designated Dr. Reena Nakra and Dr. Saloni Khera as Senior Management Personnel and re-appointed Ernst & Young LLP as internal auditors for FY 2026-27.

Dr. Lal Pathlabs Employee Stock Options

Dr. Lal Path Labs Ltd. allotted 82,750 equity shares on April 30, 2026, following the exercise of options under its Employee Stock Option Plan 2022. This allotment increases the company's paid-up share capital to 167,637,770 shares.

Dr. Lal Pathlabs Dividend

Dr. Lal Path Labs Ltd. recommended a final dividend of ₹4 per equity share (40% on face value) for FY 2025-26. The record date for payment is June 26, 2026, with the final payout expected by August 24, 2026, following shareholder approval at the AGM on July 25, 2026.

Dr. Lal Pathlabs Acquisition Worth ₹20 Cr

Dr. Lal Path Labs Ltd. will acquire a 100% stake in Mumbai-based Shahbazkers Diagnostic Centre Private Limited for ₹20 Crore. The cash transaction is expected to conclude by May 31, 2026. This acquisition aims to strengthen the company’s diagnostic service presence in Mumbai, Maharashtra.

Value

₹20.00 Cr

Execution

By May 31, 2026

Dr. Lal Pathlabs Merger & Restructuring

Dr. Lal Path Labs Ltd. is incorporating a new wholly owned subsidiary in Dubai, UAE, named Dr. Lal PathLabs FZCO. The subsidiary will focus on diagnostic services and allied activities, including potential acquisitions and joint ventures in the region. The investment will be made at face value subject to regulatory approvals.

Dr. Lal Pathlabs Earnings Call: Key Takeaways

Dr. Lal PathLabs reported strong Q4 FY26 revenue growth of 16.6% YoY, driven by volume momentum. The company is focusing on digital transformation and expanding into Tier 3+ markets.

Dr. Lal Pathlabs Earnings Call: Key Takeaways

Dr. Lal PathLabs delivered steady growth in Q4 FY26, with revenue rising 16.6% YoY to ₹703 cr. Performance was driven by high sample volumes and expansion into Tier 3+ markets.

Dr. Lal Pathlabs Results Update

Dr. Lal PathLabs Limited reported Q4 FY26 revenue of ₹703 Crore, marking 16.6% year-on-year growth. EBITDA for the quarter rose 10.5% to ₹187 Crore with a 26.6% margin, while PAT stood at ₹132 Crore. The company also declared a final dividend of 40% (Rs. 4 per share).

Value

₹703.0 Cr

Dr. Lal Pathlabs Q4 FY26 Results: Net Profit ₹132.2 Cr, Down 15.0% YoY

Dr. Lal Pathlabs Ltd reported revenue from operations of ₹702.7 Cr (+16.6% YoY) and net profit of ₹132.2 Cr (-15.0% YoY) for Q4 FY26.

Key figure

Net profit ₹132.2 Cr · -15.0% YoY

Dr. Lal Pathlabs Financial Results

Dr. Lal PathLabs Ltd. reported its FY26 audited results and recommended a final dividend of INR 4/- per share. The company also announced the 100% acquisition of Shahbazkers Diagnostic Centre for up to INR 20 Crore and the incorporation of a new subsidiary in Dubai to expand its diagnostic services footprint.

Dr. Lal Pathlabs Dividend

Dr. Lal Path Labs Ltd has scheduled a board meeting on April 30, 2026, to approve audited financial results and recommend a final dividend for FY 2025-26. The trading window remains closed until May 2, 2026.

Dr. Lal Pathlabs Dividend

Dr. Lal Path Labs Ltd. has scheduled a board meeting for April 30, 2026, to approve audited financial results and recommend a final dividend for FY 2025-26. The trading window remains closed until May 2, 2026.

Dr. Lal Pathlabs Board Meeting Outcome

Dr. Lal PathLabs Ltd informed exchanges that its Board meeting on April 30, 2026, will now also consider and recommend a Final Dividend for FY 2025-26. This is in addition to approving the audited financial results for the quarter and year ended March 31, 2026.

Dr. Lal Pathlabs Q3 FY26 Results: Net Profit ₹91.4 Cr, Down 6.8% YoY

Dr. Lal Pathlabs Ltd reported net profit of ₹91.4 Cr (-6.8% YoY) for Q3 FY26.

Key figure

Net profit ₹91.4 Cr · -6.8% YoY

Dr. Lal Pathlabs Q3 FY26 Results: Net Profit ₹91.4 Cr, Down 6.8% YoY

Dr. Lal Pathlabs Ltd reported net profit of ₹91.4 Cr (-6.8% YoY) for Q3 FY26.

Key figure

Net profit ₹91.4 Cr · -6.8% YoY